| A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine (NCT07744347) | CanSino Biologics Inc. | 2026-10-15 |
| A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector) (NCT07743411) | CanSino Biologics Inc. | 2026-09-15 |
| A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (NCT07648641) | CanSino Biologics Inc. | 2026-09-01 |
| Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (NCT07600983) | CanSino Biologics Inc. | 2026-05-24 |
| Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (NCT07203755) | CanSino Biologics Inc. | 2025-12-19 |
| A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (NCT07017777) | CanSino Biologics Inc. | 2025-11-14 |
| A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years (NCT06732583) | CanSino Biologics Inc. | 2025-11-13 |
| Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine (NCT06857370) | CanSino Biologics Inc. | 2025-03-23 |
| A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) (NCT06708286) | CanSino Biologics Inc. | 2024-12-20 |
| A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (NCT06577298) | CanSino Biologics Inc. | 2024-12-19 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds (NCT06700148) | CanSino Biologics Inc. | 2024-12-14 |
| Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine (NCT06621654) | CanSino Biologics Inc. | 2024-11-15 |
| Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants (NCT06389513) | CanSino Biologics Inc. | 2024-06-12 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (NCT06131554) | CanSino Biologics Inc. | 2024-03-20 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over (NCT06120751) | CanSino Biologics Inc. | 2024-03-20 |
| A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults (NCT06101173) | CanSino Biologics Inc. | 2024-01-15 |
| A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over (NCT06123663) | CanSino Biologics Inc. | 2023-12-20 |
| A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) (NCT06056050) | CanSino Biologics Inc. | 2023-12-06 |
| A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years (NCT05991427) | CanSino Biologics Inc. | 2023-11-07 |
| Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (NCT05935176) | CanSino Biologics Inc. | 2023-09-20 |
| A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (NCT05951725) | CanSino Biologics Inc. | 2023-08-11 |
| Clinical Trial of Recombinant Pneumococcal Protein Vaccine (NCT05622942) | CanSino Biologics Inc. | 2023-03-11 |
| A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (NCT05442684) | CanSino Biologics Inc. | 2022-11-30 |
| IH Convidecia as Second Booster Dose Against Breakthrough Infections (NCT05517642) | CanSino Biologics Inc. | 2022-09-20 |
| Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (NCT05373472) | CanSino Biologics Inc. | 2022-07-06 |
| Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (NCT05373485) | CanSino Biologics Inc. | 2022-05-17 |
| A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (NCT05169008) | CanSino Biologics Inc. | 2022-02-25 |
| A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. (NCT04916886) | CanSino Biologics Inc. | 2021-06-03 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation (NCT04840992) | CanSino Biologics Inc. | 2021-04-21 |
| Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (NCT04841369) | CanSino Biologics Inc. | 2021-04-13 |
| A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (NCT04566770) | CanSino Biologics Inc. | 2020-09-24 |
| Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above (NCT04526990) | CanSino Biologics Inc. | 2020-09-15 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada (NCT04398147) | CanSino Biologics Inc. | 2020-08-01 |
| Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (NCT04100772) | CanSino Biologics Inc. | 2020-05-18 |
| Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . (NCT04099303) | CanSino Biologics Inc. | 2020-04-28 |
| Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine (NCT04087460) | CanSino Biologics Inc. | 2020-04-10 |
| Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (NCT04313127) | CanSino Biologics Inc. | 2020-03-16 |